Objective: To ensure accurate and appropriate reporting of non-invasive prenatal testing (NIPT) results, the standard of testing should be measured and monitored by participation in external quality assessment (EQA) schemes. The findings from international pilot EQAs for NIPT for the common trisomies are presented.
| INTRODUCTION
Non-invasive prenatal testing (NIPT) based on analysis of cell free DNA (cfDNA) in maternal plasma is now recognised as being a highly sensitive screening test for trisomies 13,18, and 21. It has been implemented rapidly across the globe. 1 NIPT can be delivered using a variety of methodologies but is generally reported to have high sensitivities and specificities regardless of the platform and methodologies used.
2,3 --------------------------------------------------------------------------------------------------------------------------------
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. There are however many factors that might influence results including relatively low fetal fraction with the majority of circulating cfDNA being maternal in origin, 4 although fetal levels increase with gestation and vary with maternal weight, [5] [6] [7] [8] placental size, some pregnancy complications, and multiple pregnancies. In addition, as the majority of cfDNA in maternal plasma is maternal in origin and the fetal component derives from the placenta, 8 maternal abnormalities and abnormalities confined to the placenta may be reflected in the results. 9 Testing is largely delivered by commercial providers, either through their own laboratories or though transferring their technology to both public and private sector laboratories, although there has been some local development of testing. 10, 11 There has, however, been very little by way of standardisation.
Indeed, a recent review that included international opinions demonstrated considerable variation in reporting NIPT results and recommended development and participation in quality assurance schemes. 12 To ensure high standards of testing and reporting, it is generally accepted that it should be delivered by laboratories that are "accredited." Internationally, the standard required is defined by
ISO15189
. 13 External quality assessment (EQA), or proficiency testing (PT), provides a mechanism by which the clinical, analytical, and interpretation performance of genetic testing centres can be externally assessed against international standards and compared with other laboratories. To achieve and maintain accreditation for testing, participation in EQA(s) for all diagnostic services offered is required, and EQA performance is utilised by national accreditation bodies as a tangible measure of the quality of a laboratory's performance. Participation in EQA provides evidence of the standard of testing and reporting (including accuracy, reliability, and appropriateness), benchmarks the service against other laboratories providing comparable testing and is usually undertaken at least annually for every aspect of the diagnostic service. If a centre fails to meet the required standard (based on best practice guidelines) to pass the individual EQA distribution, the performance is designated poor, enabling the laboratory to investigate and perform a root cause analysis to rectify the problem.
EQAs are designed to check and sometimes challenge laboratory screening and/or testing for a particular genetic disease/disorder or gene/target combination. Ideally, EQA will cover all aspects of the diagnostic process through the distribution of the relevant clinical samples and associated clinical scenarios, ie, the pre-analytical, analytical, and post analytical phases (including the clinical interpretation of results). EQA in genetics is generally qualitative (detecting the presence or absence of a variant) and the EQAs discussed here are an example of where such a qualitative approach is used. EQA should be autonomous from professional and national bodies so independent external verification of the quality of service is provided as well as giving confidence to the laboratory, host institution, and users of the service that the laboratory's performance is satisfactory. 13 There are two main genetics EQA providers in Europe offering an international service: genomic quality assessment (GenQA) (https://www.genqa.org/), and the european molecular quality network (EMQN) (https://www.
emqn.org/). GenQA offers a wide repertoire of cytogenomic, genomic and clinical genetics EQAs, and EMQN, which is independent of GenQA, offers a wide range of genomic EQAs.
There are a number of unique challenges in delivering an EQA for NIPT, mainly providing EQA material for both (a) a variety of assay platforms and (b) a potentially large number of participants. The major challenge is to provide sufficient material that is of a suitable quality and has the relevant genetic aberration. The ideal EQA programme would provide every EQA participant with a batch of material that is identical to the sample type they normally receive for routine testing (ie, the same material type provided in the same quantity, collected, stored, and transported in the optimal manner). What is already known about this topic?
• To ensure laboratories deliver accurate, appropriate, and effective reporting of tests performed in their laboratories participation in external quality assessment (EQA) schemes is required by accrediting bodies.
• There is no international EQA scheme available for NIPT for aneuploidy.
What does this study add?
• EQA for the common trisomies can be successfully delivered across multiple laboratories worldwide.
• The EQA is best delivered using clinically collected maternal plasma samples which can be transported at room temperature.
• Reporting standards are very variable with key information often omitted.
• Further work is required to develop internationally acceptable EQA for NIPT aneuploidy including reporting standards.
• The high level of participation in these pilots suggests the need for continued delivery of EQA.
of artificial materials allows for the engineering of specific characteristics of interest into the sample. For example, in a Chinese NIPT EQA, the effect of low fetal fraction was investigated by limiting the amount of sheared fetal DNA in the serum. 14 However, there are some disadvantages when using artificial materials as they are not identical to real samples and consequently their performance in an assay might differ, potentially leading to a suboptimal assessment. For example, with NIPT, mechanical shearing of DNA produces fragments which differ in size distribution from those found in maternal serum, with less small DNA fragments (less than 100 bp) present. 14 The fragments produced by mechanical shearing may also be problematic for paired-end next generation sequencing (NGS) approaches. In addition, all commercially available reference materials are not currently matched for the parent/child relationship and therefore NIPT platforms using single nucleotide polymorphism (SNP) analysis is not possible using these materials.
Real clinical materials have known performance characteristics and can be tested using all clinically relevant methodologies therefore represent the gold standard. However, many laboratories require up to 4 ml of plasma to complete NIPT testing thus it is not possible to obtain sufficient amounts of donated plasma from a single pregnant patient required for a large EQA programme. Any EQA for NIPT will therefore need to use multiple samples/sources for the sample distribution, which limits the reliability of inter-laboratory comparison.
Additionally, any validation requirements reduce the volume of sample available for participants to test. In addition, as handling, transit time/conditions, and freeze/thawing are all factors that affect the relative proportions of maternal and fetal DNA in plasma, 15 careful consideration is required to ensure the EQA samples arrive in an optimal condition. In order to guarantee stability of real samples, it may be necessary to consider low temperature distribution on dry ice thereby increasing the costs and logistical difficulties of exporting the EQA materials. Finally, the restrictive availability of material from pregnancies with the rarer trisomies, eg, Edwards and Patau syndromes, are an additional limiting factor which makes offering a comprehensive range of different NIPT EQA samples a challenge.
To inform the development of an international EQA scheme, we describe two pilot EQA rounds for NIPT in singleton pregnancies delivered by the two main genetics EQA providers, GenQA and EMQN. The first uses artificial materials and the second real clinical materials.
A commercial reference material provider, SeraCare, was commissioned to manufacture bespoke artificial materials for use in the first EQA pilot.
Specific details of manufacture are held by the manufacturer who work to the relevant ISO standards. 13 All samples were independently validated by the EQA providers before distribution. One sample contained cfDNA with trisomy 21 at a fetal fraction of 4%, the second sample contained cfDNA with trisomy 18 at a fetal fraction of 10%, and the final sample was low risk of trisomy 13, 18, and 21, with a cell free fetal fraction of 12%. DNA at a concentration of 20 ng/mL, sheared to approximately 170 base pairs in size, was supplied in 1 mL aliquots of human plasma. Participating laboratories were requested to assume that the plasma has been double spun prior to receipt. If laboratories required more than 1 mL of plasma for processing, then they were instructed to dilute the sample with buffer to the required volume for testing.
The expected results were confirmed prior to EQA distribution by independently validating the samples in four laboratories using different testing protocols. The known limitation of the EQA material was that the maternal and placentally-derived cfDNA was not matched and thus laboratories using methods reliant on comparison between maternal and fetal SNPs or pair-ended NGS were not eligible to participate. The validating laboratories reported the expected genotypes but commented that the "samples did not perform as well as routine clinical samples." In order to meet the overwhelming demand for external quality assessment of NIPT, it was decided to proceed with the pilot EQA despite these limitations but without scoring of results or applying performance monitoring.
Each EQA sample was assigned an "EQA patient" name, sample identifier, reason for referral, and a clinical case scenario (see Table 1 ). Participants were informed that all samples supplied were from singleton pregnancies and NIPT for trisomy 13, 18, and 21 was requested. Laboratories were asked to analyse samples and report results using their local standard operating procedures. These reports were submitted electronically to the EQA provider websites and assessed for genotyping accuracy anonymously by a panel of NIPT experts. Assessor feedback on the genotyping and interpretation of the results, as well as the clerical accuracy of reports was provided, measured against peer ratified criteria when required (Table 2) , and an individual laboratory report returned to each laboratory. An incorrect genotype was classified as a critical error.
| EQA pilot 2
Each participating laboratory received two real patient samples (one low- temperature. The samples were not pooled and no prior validation was performed because outcome was confirmed for all cases. There was sufficient plasma available for all cases except one to distribute to at least two laboratories. Clinical case scenarios were supplied as outlined for round 1 (Table 1) , laboratories were asked to report findings using their standard format and the submitted reports were assessed as described above for round 1 except that a score (out of 2.00) was attributed for each marking category, ie, genotyping, interpretation, and clerical accuracy ( Table 2) . for the failure to obtain a reportable result could not be determined.
The overall sample failure rate was 18%.
The fetal fraction was reported by 51% of participants, whilst a further 40% did not state on the report either the fraction or whether it had been determined. The remaining 9% participants either reported the fetal fraction only for the "no abnormality detected" case, or only commented when it was not sufficient to meet their internal quality control standards.
Ninety six laboratories from 30 different countries registered to participate and 86 (89.6%) submitted EQA returns for all cases within the allotted reporting period. Nine participants failed to submit reports for either case but did not provide a reason. One laboratory submitted previously, 12 which is in line with many national recommendations (Table 2) .
Risk figures were provided in 27% and 34% of reports for Case 1
(low-risk case) and case 2 (low-risk trisomy 13 and 18, high-risk trisomy 21 case), respectively ( Figure 4) . Laboratories which provided a risk figure reported the results using a range of different terminologies ( Figure 5 ).
Three laboratories were unable to obtain a result from the material provided; one did not obtain results for either cases, a second did not obtain a reportable result for Case 1 and a third did not report results for Case 2. All remaining laboratories submitted a result for both cases and the overall sample failure rate in this EQA pilot was 2.3%.
| Report format for both pilot EQA rounds
The format of the reports was very variable for both pilot EQA rounds with essential information missing from the main body of the text, making it difficult to find. Many reports embedded essential information (eg, the requirement to confirm the high-risk result by invasive testing) either in the footer, a rider, or just generally in a nonprominent FIGURE 3 Description of the methodologies tested in pilot 2 as described by participants in their reports showing the wide variation in terminology used, some generic and some using brand names Although the majority of laboratories provided details of the test performed, there was considerable variation in the type of information provided ( Table 2) . Information on the bioinformatic work-up was not given in the majority of reports, and laboratories that were using a commercial test did not describe the methodology of the assay or give a ref-
erence to inform the reader where the information could be accessed.
| DISCUSSION
We have successfully demonstrated that EQA can be delivered to laboratories performing NIPT for the three common trisomies based on analysis of cfDNA in maternal plasma. The first used artificially created materials which were not applicable to all laboratories and had a higher failure rate than the second, which used real maternal plasma samples applicable to all providers and with a low critical error rate need for more standardisation and EQA in this field. For these EQAs, we based the standard on the consensus on report content that has recently been published to evaluate results, 12 but these should be reviewed and endorsed EQA providers internationally before further evaluation.
In addition to essential elements required in an NIPT report such as method(s) used, whether targeted or whole genome sequencing, to indicate the extent of testing fetal fraction is another important parameter that may be included in a report. However, there is considerable variation in the way the testing methodology was described, and some providers using a defined fetal fraction as a cut-off to fail results; others using it as a quality measure and others not commenting at all. 8, 19 It is important that there is no ambiguity in the language when describing the results. A third of laboratories stated the result was either high or low risk whilst two-thirds provided some estimation of this risk.
Some centres gave a precise risk calculation but this figure was not always consistent with the sensitivity of the assay. Overall, there was considerable variation in the risk calculation provided by laboratories regardless of whether it was a high or low risk result. Given the disparity seen and recent debate from lay support groups, further discussion on the terminology used is required, but terms "high-risk" and "low risk"
or "high chance" or "low chance" rather than "normal/abnormal" or "positive/negative" are likely to be more acceptable. The adoption of these terms by laboratories will need to be assessed in future EQA distributions.
Since delivering these pilot EQAs, an improved artificial reference sample has been developed that allows pairing of the maternal and fetal genotypes. This means that it is potentially usable on all platforms currently available. As sourcing clinical samples for large NIPT EQAs is going to be challenging, access to suitable manufactured materials has significant potential advantages. We therefore plan a further pilot EQAs which will distribute both real plasma samples and artificial samples to allow comparison and inclusion of all testing laboratories.
In conclusion, two pilot EQAs for NIPT for aneuploidy in singleton pregnancies have been successfully run and shown that using maternal plasma samples shipped at ambient temperature is superior and more widely applicable. However, there are practical issues that need to be addressed before initiating a formal EQA over a wider range of laboratories, including how to source sufficient plasma samples in the future and terminology to be used in reporting. The significant variation in reporting standards will need to be addressed in future EQAs and further discussion is required to harmonise the approach across the globe, but the data we report here has highlighted the issues that need to be addressed in future EQAs. Finally, the study reported here describes piloting EQA in singleton pregnancies, clearly there are other situations that will require evaluation including multiple pregnancies and those conceived following assisted conception.
